✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Tesamorelin / Ipamorelin GH-Axis Blend
The Tesamorelin + Ipamorelin blend combines a GHRH analogue (Tesamorelin) with a selective ghrelin-receptor agonist (Ipamorelin), studied for complementary stimulation of the GH/IGF-1 axis.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
The Tesamorelin + Ipamorelin blend combines a GHRH analogue (Tesamorelin) with a selective ghrelin-receptor agonist (Ipamorelin), studied for complementary stimulation of the GH/IGF-1 axis.
Each component is independently characterized in the laboratory literature; the blend is studied as a combined preparation.
Third-party tested for purity, ID, quantity.
This blend combines Tesamorelin, a stabilized GHRH analogue, with Ipamorelin, a selective growth-hormone secretagogue. Research framing draws on the established literature for each peptide and on the complementary GHRH + secretagogue model of GH-axis stimulation.
The blend is studied as a combined preparation in GH/IGF-1 axis research models under structured conditions.
The blend is formulated from two independently studied GH-axis peptides with distinct research lineages — Tesamorelin as a GHRH analogue and Ipamorelin as a selective ghrelin-receptor agonist.
Research framing for the Tesamorelin + Ipamorelin blend draws on the combined literature of its components across GHRH-receptor and ghrelin-receptor signaling models of the GH/IGF-1 axis under controlled conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of tesamorelin ipamorelin blend. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
PubMedEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291–4304.
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$50.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$60.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$90.00
